Modelling the long-term benefits of photodynamic therapy (PDT) with Verteporfin for age-related macular degeneration (AMD)
Age related macular degeneration (AMD) is the leading cause of blindness in the United Kingdom and the rest of the western world. It occurs in 15% to 30% of individuals over 75 years of age. About 15% of these patients develop a more aggressive wet form of the disease that causes severe loss of vision. This report contains estimates of the benefits of photodynamic therapy (PDT) with verteporfin therapy using a modeling approach based on clinical trial data. While this report covers only the effects of the treatment, the model built was customizable so that it could be populated with local cost data. This made it possible to use the model to help inform local formulary decisions.
|Date of creation:||Mar 2002|
|Contact details of provider:|| Postal: York Y010 5DD|
Phone: (01904) 321401
Web page: http://www.york.ac.uk/che
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:chy:respap:187chedp. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Gill Forder)
If references are entirely missing, you can add them using this form.